Your support fuels our research to #EndALS!


TDI 207

This small molecule is being tested by scientists at the ALS Therapy Development Institute for its potential to help support the unfolded protein response in ALS patients. 


Type: Small Molecule
Stage: Preclinical
Status: Active
Sponsor: ALS Therapy Development Institute

TDI Says:

Since adding it in January of 2015, we've been able to rapidly move this compound into efficacy testing in SOD1 mice. We are hopeful it will show promise as a treatment for ALS.

Comment on this Topic

(All comments are moderated before they appear here.)